TY - JOUR
T1 - Sjögren Syndrome With Associated Lymphocytic Interstitial Pneumonia Successfully Treated With Tacrolimus and Abatacept as an Alternative to Rituximab
AU - Thompson, Grace
AU - Mclean-Tooke, Andrew
AU - Wrobel, Jeremy
AU - Lavender, Melanie
AU - Lucas, Michaela
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Interstitial lung disease (ILD) is a significant complication of Sjögren syndrome (SS) associated with increased morbidity and mortality. The mainstay of treatment remains corticosteroid administration, with or without additional immunosuppressive therapies. Preliminary studies in SS have shown benefit in glandular and serologic parameters following treatment with the CTLA4 immunoglobulin fusion protein abatacept. Topical tacrolimus has been effective for ocular symptoms in SS, but systemic therapy has not been reported. We describe the first case, to our knowledge, of the successful use of a combination of systemic tacrolimus and abatacept in severe refractory SS and related ILD.
AB - Interstitial lung disease (ILD) is a significant complication of Sjögren syndrome (SS) associated with increased morbidity and mortality. The mainstay of treatment remains corticosteroid administration, with or without additional immunosuppressive therapies. Preliminary studies in SS have shown benefit in glandular and serologic parameters following treatment with the CTLA4 immunoglobulin fusion protein abatacept. Topical tacrolimus has been effective for ocular symptoms in SS, but systemic therapy has not been reported. We describe the first case, to our knowledge, of the successful use of a combination of systemic tacrolimus and abatacept in severe refractory SS and related ILD.
KW - abatacept
KW - interstitial lung disease
KW - Sjögren syndrome
KW - tacrolimus
UR - http://www.scopus.com/inward/record.url?scp=85042941902&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2017.12.010
DO - 10.1016/j.chest.2017.12.010
M3 - Article
C2 - 29519308
AN - SCOPUS:85042941902
SN - 0012-3692
VL - 153
SP - e41-e43
JO - Chest
JF - Chest
IS - 3
ER -